ProfileGDS5678 / 1438501_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 35% 18% 16% 18% 16% 16% 18% 15% 18% 17% 18% 17% 17% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5908924
GSM967853U87-EV human glioblastoma xenograft - Control 22.7849735
GSM967854U87-EV human glioblastoma xenograft - Control 32.4300218
GSM967855U87-EV human glioblastoma xenograft - Control 42.352716
GSM967856U87-EV human glioblastoma xenograft - Control 52.3923118
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4553416
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4226116
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4104918
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3393615
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4247418
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4124317
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4103718
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4177217
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4169417